Aeras awarded €11.7 million ($16 million) grant from Dutch government
Advertisement
The Aeras Global TB Vaccine Foundation announced that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional €11.7 million over four years (2011-2014) to further its efforts to develop new vaccines to help combat the global epidemic of tuberculosis.
This expression of support represents a continuation in the long-standing collaboration between the Dutch government, Aeras and its research partners. This is the second grant to Aeras from the Netherlands Ministry of Foreign Affairs, representing a total commitment of €30.4 million to Aeras since 2006.
"The forward movement of TB vaccine candidates in the development pipeline owes a great deal to the generous support of the Dutch Ministry of Foreign Affairs and the people of the Netherlands," said Jim Connolly, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation. "We are extraordinarily grateful for their foresight and steadfast support of these potentially life saving efforts."
New TB vaccines are urgently needed. The currently available vaccine, Bacille Calmette-Guérin, provides some protection against pediatric TB but is unreliable in protecting adult pulmonary TB, the most common form of the disease. As a product development partnership, Aeras collaborates and facilitates research in conjunction with numerous scientists in academic, pharmaceutical, biotechnology and government research centers around the world to develop safer and more immunogenic TB vaccines. Globally, nine TB vaccine candidates are currently undergoing clinical testing, and of those, four are directly supported and led by Aeras and its network.
Since the Netherlands's first grant to Aeras and its partners in 2006, four TB vaccine candidates in Aeras' product portfolio have moved into clinical testing in Europe, North America and Africa. Two of those are at the Phase II proof of concept stage and will enroll infants in South Africa, Kenya, Uganda and Mozambique.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Merck Serono and Illumina Enter Strategic Collaboration for Diagnostics in Oncology
Loss of the Y chromosome discovered as a new risk factor for heart disease - Men who lose their Y chromosome in part of their blood cells have an increased risk of cardiovascular disease
Bruker announces acquisition of a spin-off from Ghent University - Acquisition expands nuclear molecular imaging portfolio
Researchers discover way to inhibit major cancer gene
Swiss biotechnology startup HAYA Therapeutics announces collaboration with Lilly - Discovery of novel regulatory genomic targets for obesity and related metabolic conditions using proprietary RNA platform
Medigenomix Acquires an Exclusive License for another Genetic Polymorphisms in G-Proteins for Applications in Pharmacogenetics
Breakthrough: Prospect of blood test for Parkinson’s disease for the first time - A new method reliably detects protein changes in blood that are typical of Parkinson's disease: "The results are really sensational"
Evotec and Bayer partner to develop new treatments to fight kidney diseases
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
Vaccine-induced CD4 T cells have adverse effect in a mouse model of infection - Research offers a 'cautionary tale' for the development of CD4 T cell vaccines
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b
